Stock 600299 BLUESTAR ADISSEO COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Financials Bluestar Adisseo Company

Equities

600299

CNE000001253

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 03:30:00 30/04/2024 am IST 		5-day change 1st Jan Change
9.98 CNY +2.78% Intraday chart for Bluestar Adisseo Company +4.94% +24.75%
25/04 Bluestar Adisseo Company Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
25/04 Bluestar Adisseo Company announced that it expects to receive CNY 3 billion in funding CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 29,662 30,869 33,041 22,153 21,455 26,765 - -
Enterprise Value (EV) 1 29,662 29,026 31,861 23,338 22,310 27,966 27,901 26,874
P/E ratio - 23 x 22.4 x 18 x 400 x 30.9 x 23.5 x 18.1 x
Yield 1.41% 1.53% 1.44% 1.83% 0.75% 0.83% 1.34% 2.51%
Capitalization / Revenue 2.66 x 2.59 x 2.57 x 1.52 x 1.63 x 1.76 x 1.55 x 1.48 x
EV / Revenue 2.66 x 2.44 x 2.48 x 1.61 x 1.69 x 1.84 x 1.62 x 1.48 x
EV / EBITDA - 9.17 x 9.96 x 7.96 x 13.4 x 10.2 x 8.63 x 7.3 x
EV / FCF - - - - - - - -
FCF Yield - - - - - - - -
Price to Book 2.15 x 2.21 x 2.34 x 1.48 x 1.43 x 1.67 x 1.61 x 1.49 x
Nbr of stocks (in thousands) 26,81,901 26,81,901 26,81,901 26,81,901 26,81,901 26,81,901 - -
Reference price 2 11.06 11.51 12.32 8.260 8.000 9.980 9.980 9.980
Announcement Date 13/02/20 10/02/21 30/03/22 15/02/23 28/03/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 11,135 11,910 12,869 14,529 13,184 15,168 17,214 18,124
EBITDA 1 - 3,164 3,200 2,931 1,669 2,730 3,231 3,681
EBIT 1 1,589 2,046 2,082 1,503 68.37 1,244 1,646 2,054
Operating Margin 14.27% 17.18% 16.18% 10.34% 0.52% 8.2% 9.56% 11.33%
Earnings before Tax (EBT) 1 - 1,998 - 1,541 64.44 1,146 1,491 1,940
Net income 1 - 1,352 - 1,247 52.17 864.9 1,141 1,471
Net margin - 11.35% - 8.58% 0.4% 5.7% 6.63% 8.12%
EPS 2 - 0.5000 0.5500 0.4600 0.0200 0.3235 0.4248 0.5502
Free Cash Flow - - - - - - - -
FCF margin - - - - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share 2 0.1560 0.1760 0.1780 0.1510 0.0600 0.0833 0.1334 0.2501
Announcement Date 13/02/20 10/02/21 30/03/22 15/02/23 28/03/24 - - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2022 S2 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2023 S2 2024 Q1 2024 Q2 2024 S1 2024 Q3 2024 Q4 2024 S2 2025 Q1 2025 Q2 2025 S1 2025 S2
Net sales 1 3,526 - - 3,605 3,729 7,334 3,152 3,176 3,286 3,569 6,855 3,496 3,970 8,314 3,800 3,416 7,299 - - 8,232 8,232
EBITDA 1 656.5 - - 590.3 - - - - - - - - 645 - 677.2 572.9 - - - - -
EBIT 1 402.1 - - 358.4 30 388.4 19.13 43.09 1,410 80.07 6.148 367 309.4 1,048 341.6 237.3 271.2 - - 554.4 554.4
Operating Margin 11.4% - - 9.94% 0.8% 5.3% 0.61% 1.36% 42.92% 2.24% 0.09% 10.5% 7.79% 12.61% 8.99% 6.95% 3.72% - - 6.73% 6.73%
Earnings before Tax (EBT) 1 - - - - - - 17.16 37.96 -73.19 82.51 - 359.4 295 - 346.9 177.1 - - - - -
Net income 1 - - - - - - 1.488 31.91 -67.81 86.57 - 276.9 221.3 - 260.2 124.9 - - - - -
Net margin - - - - - - 0.05% 1% -2.06% 2.43% - 7.92% 5.57% - 6.85% 3.66% - - - - -
EPS 2 0.0800 - - 0.1100 0.0300 - 0.000600 0.009400 -0.0200 0.0300 0.0100 0.1000 0.0825 0.3200 0.0970 0.0466 0.0300 - - 0.1400 0.1400
Dividend per Share 2 0.1780 - - - 0.1510 - - - - 0.0600 - - - - - - - 0.0376 0.0376 - -
Announcement Date 30/03/22 28/04/22 28/07/22 27/10/22 15/02/23 15/02/23 26/04/23 04/08/23 27/10/23 28/03/24 28/03/24 25/04/24 - - - - - - - - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - 1,186 855 1,200 1,136 109
Net Cash position 1 - 1,843 1,180 - - - - -
Leverage (Debt/EBITDA) - - - 0.4045 x 0.5125 x 0.4398 x 0.3514 x 0.0296 x
Free Cash Flow - - - - - - - -
ROE (net income / shareholders' equity) 7.24% 9.97% 10.5% 8.71% 0.35% 5.31% 8.15% 10.1%
ROA (Net income/ Total Assets) 4.66% 6.48% - - 0.24% 3.6% 4.3% -
Assets 1 - 20,877 - - 21,432 24,026 26,527 -
Book Value Per Share 2 5.140 5.200 5.260 5.570 5.610 5.970 6.190 6.710
Cash Flow per Share 2 0.9500 1.010 0.9700 0.6400 1.030 0.7700 0.8700 -
Capex 1 1,237 1,310 2,313 1,531 1,447 1,279 1,765 1,279
Capex / Sales 11.11% 11% 17.98% 10.53% 10.97% 8.43% 10.25% 7.06%
Announcement Date 13/02/20 10/02/21 30/03/22 15/02/23 28/03/24 - - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Bluestar Adisseo Company

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
9.98 CNY
Average target price
9.81 CNY
Spread / Average Target
-1.70%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Veterinary Drugs

1st Jan change Capi.
BLUESTAR ADISSEO COMPANY Stock Bluestar Adisseo Company
+24.75% 3.7B
ELANCO ANIMAL HEALTH INCORPORATED Stock Elanco Animal Health Incorporated
-9.19% 6.64B
VIRBAC Stock Virbac
-1.11% 3.12B
VIMIAN GROUP AB Stock Vimian Group AB
+6.08% 1.45B
JINYU BIO-TECHNOLOGY CO., LTD. Stock Jinyu Bio-technology Co., Ltd.
-15.13% 1.37B
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD. Stock China Animal Husbandry Industry Co., Ltd.
-25.63% 1.24B
VETOQUINOL SA Stock Vetoquinol SA
-7.62% 1.21B
WUHAN KEQIAN BIOLOGY CO.,LTD Stock Wuhan Keqian Biology Co.,Ltd
-10.84% 1.17B
TIANJIN RINGPU BIO-TECHNOLOGY CO.,LTD. Stock Tianjin Ringpu Bio-Technology Co.,Ltd.
-.--% 1.05B
SWEDENCARE AB Stock Swedencare AB
-7.07% 820M
Veterinary Drugs
  1. Stock Market
  2. Equities
  3. 600299 Stock
  4. Financials Bluestar Adisseo Company